Enovis Corp

NYSE ENOV

Data sourced from

and

Daily

Download Data

Enovis Corp Price to Sales Ratio (P/S) on June 03, 2024: 1.48

Enovis Corp Price to Sales Ratio (P/S) is 1.48 on June 03, 2024, a -21.41% change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Enovis Corp 52-week high Price to Sales Ratio (P/S) is 2.19 on July 12, 2023, which is 47.47% above the current Price to Sales Ratio (P/S).
Enovis Corp 52-week low Price to Sales Ratio (P/S) is 1.46 on October 26, 2023, which is -1.60% below the current Price to Sales Ratio (P/S).
Enovis Corp average Price to Sales Ratio (P/S) for the last 52 weeks is 1.84.

NYSE: ENOV

Enovis Corp

CEO	Mr. Mitchell P. Rales
IPO Date	May 8, 2008
Location	United States
Headquarters	2711 Centerville Road, Wilmington, DE, United States, 19808
Employees	6,550
Sector	Industrials
Industry	Specialty industrial machinery

Description

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

Key trends